PMID- 9364981
OWN - NLM
STAT- MEDLINE
DCOM- 19980112
LR  - 20071114
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 78
IP  - 4
DP  - 1997 Oct
TI  - High antibody levels to prothrombin imply a risk of deep venous thrombosis and 
      pulmonary embolism in middle-aged men--a nested case-control study.
PG  - 1178-82
AB  - Antibodies against phospholipid-binding plasma proteins, such as 
      beta2-glycoprotein I (beta2-GPI) and prothrombin, are associated with 
      thromboembolic events in patients with systemic lupus erythematosus and also in 
      subjects with no evident underlying diseases. We wanted to examine whether 
      increased levels of antibodies to negatively-charged phospholipids (cardiolipin), 
      to phospholipid-binding plasma proteins beta2-GPI and prothrombin and to oxidised 
      low-density lipoprotein (LDL) were associated with risk of deep venous thrombosis 
      or pulmonary embolism in subjects with no previous thrombosis. The antibodies 
      were measured in stored serum samples from 265 cases of deep venous thrombosis of 
      the lower extremity or pulmonary embolism occurring during a median follow-up of 
      about 7 years and from 265 individually matched controls. The study subjects were 
      middle-aged men participating in a cancer prevention trial of alpha-tocopherol 
      and beta-carotene and the cases of thromboembolic events were identified from 
      nationwide Hospital Discharge Register. The risk for thrombotic events was 
      significantly increased only in relation to antiprothrombin antibodies. As 
      adjusted for body mass index, number of daily cigarettes and history of chronic 
      bronchitis, myocardial infarction and heart failure at baseline, the odds ratio 
      per one unit of antibody was 6.56 (95% confidence interval 1.73-25.0). The seven 
      highest individual optical density-unit values of antiprothrombin antibodies were 
      all confined to subjects with thromboembolic episodes. In conclusion, the present 
      nested case-control study showed that high autoantibody levels against 
      prothrombin implied a risk of deep venous thrombosis and pulmonary embolism and 
      could be involved in the development of the thrombotic processes.
FAU - Palosuo, T
AU  - Palosuo T
AD  - National Public Health Institute, Helsinki, Finland.
FAU - Virtamo, J
AU  - Virtamo J
FAU - Haukka, J
AU  - Haukka J
FAU - Taylor, P R
AU  - Taylor PR
FAU - Aho, K
AU  - Aho K
FAU - Puurunen, M
AU  - Puurunen M
FAU - Vaarala, O
AU  - Vaarala O
LA  - eng
GR  - N01-CN-45165/CN/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Antibodies, Anticardiolipin)
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Autoantibodies)
RN  - 0 (Glycoproteins)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (beta 2-Glycoprotein I)
RN  - 0 (oxidized low density lipoprotein)
RN  - 1406-18-4 (Vitamin E)
RN  - 9001-26-7 (Prothrombin)
SB  - IM
MH  - Aged
MH  - Antibodies, Anticardiolipin/blood
MH  - Antibodies, Antiphospholipid/blood/immunology
MH  - Antibody Specificity
MH  - Autoantibodies/*blood/immunology
MH  - Bronchitis/epidemiology
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Comorbidity
MH  - Double-Blind Method
MH  - Glycoproteins/immunology
MH  - Humans
MH  - Lipoproteins, LDL/immunology
MH  - Lung Neoplasms/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/epidemiology
MH  - Prothrombin/*immunology
MH  - Pulmonary Embolism/blood/epidemiology/*immunology
MH  - Risk
MH  - Risk Factors
MH  - Smoking/blood/immunology
MH  - Thrombophilia/blood/*immunology
MH  - Thrombophlebitis/blood/epidemiology/*immunology
MH  - Vitamin E/therapeutic use
MH  - beta 2-Glycoprotein I
EDAT- 1997/11/19 00:00
MHDA- 1997/11/19 00:01
CRDT- 1997/11/19 00:00
PHST- 1997/11/19 00:00 [pubmed]
PHST- 1997/11/19 00:01 [medline]
PHST- 1997/11/19 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1997 Oct;78(4):1178-82.